Benitec Financial Statements From 2010 to 2026

Stocks . USA . 
Stock . Benitec Biopharma Ltd
BNTC Stock  USD 12.41  0.18  1.43%   
Benitec Biopharma's financial statements offer valuable quarterly and annual insights to potential investors, highlighting the company's current and historical financial position, overall management performance, and changes in financial standing over time. Key fundamentals influencing Benitec Biopharma's valuation are provided below:
Market Capitalization
431.3 M
Enterprise Value Revenue
10.5 K
Revenue
7 K
Earnings Share
(1.09)
Quarterly Revenue Growth
0.125
We have found one hundred twenty available fundamental signals for Benitec Biopharma Ltd, which can be analyzed and compared to other ratios and to its rivals. Investors should ensure to validate all of Benitec Biopharma's prevailing performance against the performance from 2010 to 2026 to make sure the company is sustainable down the road. The current year's Market Cap is expected to grow to about 400.3 M. The current year's Enterprise Value is expected to grow to about 308.8 M

Benitec Biopharma Total Revenue

0.0

Check Benitec Biopharma financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Benitec Biopharma's main balance sheet or income statement drivers, such as Depreciation And Amortization of 59.3 K, Interest Expense of 1.1 M or Selling General Administrative of 28.3 M, as well as many indicators such as Price To Sales Ratio of 64.14, Dividend Yield of 0.0012 or PTB Ratio of 6.36. Benitec financial statements analysis is a perfect complement when working with Benitec Biopharma Valuation or Volatility modules.
  
Build AI portfolio with Benitec Stock
Check out the analysis of Benitec Biopharma Correlation against competitors.

Benitec Biopharma Balance Sheet

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Total Assets120.3 M114.5 M37.4 M
Slightly volatile
Other Current Liabilities1.4 M1.4 M1.2 M
Slightly volatile
Total Current Liabilities2.2 M2.1 M1.9 M
Slightly volatile
Total Stockholder Equity117.5 M111.9 M35.3 M
Slightly volatile
Property Plant And Equipment Net1.2 M1.1 M533.1 K
Slightly volatile
Accounts Payable219.6 K231.2 K554.3 K
Very volatile
Cash118 M112.4 M34.9 M
Slightly volatile
Non Current Assets Total642.8 K1.2 M562.5 K
Slightly volatile
Cash And Short Term Investments118 M112.4 M34.9 M
Slightly volatile
Net Receivables28.2 K29.7 K655.6 K
Pretty Stable
Common Stock Total Equity85590061.2 M
Slightly volatile
Common Stock Shares Outstanding43.7 M41.6 M8.1 M
Slightly volatile
Liabilities And Stockholders Equity120.3 M114.5 M37.4 M
Slightly volatile
Other Current Assets614.6 K666.9 K959.2 K
Slightly volatile
Total Liabilities2.3 M2.6 M2 M
Slightly volatile
Property Plant And Equipment Gross3 M2.8 M983.5 K
Slightly volatile
Total Current Assets119 M113.3 M36.8 M
Slightly volatile
Common Stock1.7 K1.8 K54.4 M
Slightly volatile
Property Plant Equipment511.4 K705 K447.5 K
Slightly volatile
Net Tangible Assets172.7 K181.8 K15.4 M
Slightly volatile
Net Invested Capital117.5 M111.9 M32.5 M
Slightly volatile

Benitec Biopharma Income Statement

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Depreciation And Amortization59.3 K62.4 K1.4 M
Slightly volatile
Selling General Administrative28.3 M26.9 M9.8 M
Slightly volatile
Other Operating Expenses50.4 M48 M17.8 M
Slightly volatile
Research Development22.1 M21.1 M9.1 M
Slightly volatile
Total Operating Expenses50 M47.6 M17.6 M
Slightly volatile
Interest Income5.1 K5.4 K224.7 K
Slightly volatile
Reconciled Depreciation339.1 K455.4 K268.8 K
Slightly volatile
Selling And Marketing Expenses221.6 K249.3 K272.1 K
Slightly volatile

Benitec Biopharma Cash Flow Statement

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Begin Period Cash Flow61.5 M58.6 M19.7 M
Slightly volatile
Capital Expenditures15.4 K16.2 K138.8 K
Slightly volatile
End Period Cash Flow118.2 M112.5 M34.9 M
Slightly volatile
Depreciation268.2 K455.4 K217 K
Slightly volatile
Change To Netincome591.5 K409.5 K611.6 K
Very volatile
Stock Based Compensation21 M20 M3.9 M
Slightly volatile

Financial Ratios

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Price To Sales Ratio64.1467.52244
Very volatile
Dividend Yield0.00120.00140.0015
Slightly volatile
PTB Ratio6.363.927.0846
Very volatile
Days Sales Outstanding292308626
Pretty Stable
Book Value Per Share2.943.09364
Slightly volatile
Average Payables493.1 K855 K682 K
Slightly volatile
Stock Based Compensation To Revenue4.285.423.4739
Slightly volatile
Capex To Depreciation0.04970.05230.6368
Slightly volatile
PB Ratio6.363.927.0846
Very volatile
EV To Sales42.2844.5192
Very volatile
Sales General And Administrative To Revenue86.0381.9446.7663
Slightly volatile
Research And Ddevelopement To Revenue16115371.2745
Slightly volatile
Capex To Revenue0.01140.0120.4271
Very volatile
Cash Per Share2.953.1339
Slightly volatile
Income Quality1.230.721.1811
Slightly volatile
Current Ratio66.0262.8724.3494
Pretty Stable
Tangible Book Value Per Share2.943.09364
Slightly volatile
Receivables Turnover1.171.233.5239
Very volatile
Shareholders Equity Per Share2.943.09364
Slightly volatile
Debt To Equity0.00750.00790.205
Pretty Stable
Capex Per Share5.0E-46.0E-41.3044
Slightly volatile
Average Receivables1.6 M2.5 M2 M
Slightly volatile
Revenue Per Share0.05910.062210.7006
Slightly volatile
Interest Debt Per Share0.02560.0271.0613
Slightly volatile
Debt To Assets0.00930.00980.0382
Very volatile
Graham Number130146159
Slightly volatile
Operating Cycle2923084.4 K
Slightly volatile
Price Book Value Ratio6.363.927.0846
Very volatile
Ebt Per Ebit0.720.820.8737
Pretty Stable
Company Equity Multiplier0.880.922.3498
Pretty Stable
Total Debt To Capitalization0.00740.00780.0809
Pretty Stable
Debt Equity Ratio0.00750.00790.205
Pretty Stable
Quick Ratio51.6649.221.9939
Pretty Stable
Net Income Per E B T0.750.850.923
Slightly volatile
Cash Ratio51.2648.8221.1952
Pretty Stable
Days Of Sales Outstanding292308626
Pretty Stable
Free Cash Flow Operating Cash Flow Ratio1.111.151.0206
Slightly volatile
Price To Book Ratio6.363.927.0846
Very volatile
Fixed Asset Turnover0.130.144.1971
Slightly volatile
Debt Ratio0.00930.00980.0382
Very volatile
Price Sales Ratio64.1467.52244
Very volatile
Asset Turnover0.01440.01510.0534
Very volatile
Price Fair Value6.363.927.0846
Very volatile

Benitec Biopharma Valuation Data

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Market Cap400.3 M381.3 M163.8 M
Pretty Stable
Enterprise Value308.8 M294.1 M135.1 M
Very volatile

Benitec Fundamental Market Drivers

Benitec Upcoming Events

12th of February 2024
Upcoming Quarterly Report
View
31st of December 2023
Next Fiscal Quarter End
View

About Benitec Biopharma Financial Statements

Benitec Biopharma stakeholders use historical fundamental indicators, such as Benitec Biopharma's revenue or net income, to determine how well the company is positioned to perform in the future. Although Benitec Biopharma investors may analyze each financial statement separately, they are all interrelated. For example, changes in Benitec Biopharma's assets and liabilities are reflected in the revenues and expenses on Benitec Biopharma's income statement, which ultimately affect the company's gains or losses. Understanding these patterns can help in making the right long-term investment decisions in Benitec Biopharma Ltd. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Current Deferred Revenue-1.2 M-1.3 M
Cost Of Revenue455.4 K478.2 K
Stock Based Compensation To Revenue 5.42  4.28 
Sales General And Administrative To Revenue 81.94  86.03 
Research And Ddevelopement To Revenue 153.29  160.95 
Capex To Revenue 0.01  0.01 
Revenue Per Share 0.06  0.06 
Ebit Per Revenue(292.58)(277.95)

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.
FSLYFastly Class A
MOBMobilicom Limited American
CMGChipotle Mexican Grill
When determining whether Benitec Biopharma offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Benitec Biopharma's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Benitec Biopharma Ltd Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Benitec Biopharma Ltd Stock:
How To Invest In Benitec
Details
Is Benitec Stock a good investment?
Details
What is Benitec Biopharma's Net Worth?
Details
Largest Biotechnology Companies
View
Largest Pharmaceuticals, Biotechnology & Life Sciences Companies
View
Check out the analysis of Benitec Biopharma Correlation against competitors.
You can also try the Instant Ratings module to determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance.
Will Biotechnology sector continue expanding? Could Benitec diversify its offerings? Factors like these will boost the valuation of Benitec Biopharma. Projected growth potential of Benitec fundamentally drives upward valuation adjustments. Accurate valuation requires analyzing both current fundamentals and future growth trajectories. Every Benitec Biopharma data point contributes insight, yet successful analysis hinges on identifying the most consequential variables.
Earnings Share
(1.09)
Revenue Per Share
0.003
Quarterly Revenue Growth
0.125
Return On Assets
(0.35)
Return On Equity
(0.53)
The market value of Benitec Biopharma is measured differently than its book value, which is the value of Benitec that is recorded on the company's balance sheet. Investors also form their own opinion of Benitec Biopharma's value that differs from its market value or its book value, called intrinsic value, which is Benitec Biopharma's true underlying value. Seasoned market participants apply comprehensive analytical frameworks to derive fundamental worth and identify mispriced opportunities. Because Benitec Biopharma's market value can be influenced by many factors that don't directly affect Benitec Biopharma's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Altman
Z Score
Details
Piotroski
F Score
Details
Beneish
M Score
Details
Financial
Analysis
Details
Buy or Sell
Advice
Details
Earnings
Projections
Details
It's important to distinguish between Benitec Biopharma's intrinsic value and market price, which are calculated using different methodologies. Investment decisions regarding Benitec Biopharma should consider multiple factors including financial performance, growth metrics, competitive position, and professional analysis. Meanwhile, Benitec Biopharma's quoted price indicates the marketplace figure where supply meets demand through bilateral consent.
Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions
 
Feedback Blog
Made with optimal in San Francisco
2026 Macroaxis LLC
COMMON DESTINATIONS
MAIN CATEGORIES
COMPANY